These evidence, together with the increasing interest in the anticancer properties of metal-based compounds (Chen et al., 2017), have recently lead to the development of innovative gold (III) complexes of prasugrel, a newer oral P2Y12R inhibitor, with promising chemotherapeutic activities (Benkli, 2016).